Condition: IDH-mutant Grade 2 or 3 Astrocytoma · Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
The main goal of VIGOR is to demonstrate that vorasidenib maintenance therapy improves locally assessed progression-free survival (PFS) from enrolment compared to placebo in patients with IDH-mutant, CNS5 WHO Grade 2 or 3 astrocytoma following the completion of first-line chemoradiotherapy. The primary endpoint is Progression-free survival (PFS), as assessed locally from the date of enrolment using the RANO 2.0 criteria. In this a comparative, randomized (1:1), triple blinded, multicentre phase III superiority trial with one stopping rule for efficacy and futility after end of enrolment, participants in the experimental arm will receive vorasidenib orally once daily at a dose of 40 mg in continuous 28-day cycles while participants in the control arm will receive a matched oral placebo once daily in continuous 28-day cycles
This description comes directly from the study's public registry record.
EORTC HQ · +32 2 774611 · eortc@eortc.org
Always discuss trial participation with your own doctor first.
| Medical University of Innsbruck | Innsbruck, Austria | Not Yet Recruiting |
| Kepler University Hospital - Neuromed campus | Linz, Austria | Recruiting |
| Medical University of Vienna | Vienna, Austria | Recruiting |
| Universitair Ziekenhuis Brussel | Brussels, Belgium | Recruiting |
| Ghent University Hospital | Ghent, Belgium | Recruiting |
| U.Z. Leuven - Campus Gasthuisberg | Leuven, Belgium | Recruiting |
| Masaryk Memorial Cancer Institute | Brno, Czechia | Recruiting |
| Universitary hospital Bordeaux France | Bordeaux, France | Recruiting |
| CHU Lyon - Hopital neurologique Pierre Wertheimer | Lyon, France | Recruiting |
| Marseille APHM | Marseille, France | Not Yet Recruiting |
| Assistance Publique Hopitaux de Paris APHP - Sorbonne | Paris, France | Not Yet Recruiting |
| Oncopole Claudius Regaud, IUCT-Oncopole | Toulouse, France | Not Yet Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06809322